; and (2) is designated to be used by the Foundation to conduct or support early-stage research on the development of products to treat or prevent a disease attributable to a multi-drug resistant bacterial or fungal pathogen. (i) Relation to pediatric exclusivity Any extension of a period under subsection (c) shall be in addition to any extension of the period under section 505A of this Act, and any reference to a period in subsection (c) is deemed to be a reference to the period as extended under such section 505A, if applicable. (j) Critical need antimicrobial priorities (1) Committee on Developing Critical Need Antimicrobials Not later than 60 days after the date of enactment of the Re-Valuing Anti-Microbial Products Act of 2018 , the Secretary shall establish a Committee on Developing Critical Need Antimicrobials. (2) Membership The members of the Committee shall include— (A) one representative of the Food and Drug Administration; (B) one representative of the Centers for Disease Control and Prevention; (C) one representative of the Biomedical Advanced Research and Development Authority; and (D) five representatives of the community of other stakeholders with research, commercialization, clinical, public health, and economic expertise in the field of antimicrobial resistance, which representatives shall include at least one physician with experience treating infections caused by multidrug resistant organisms. (3) Duties The Committee shall— (A) not later than 60 days after all of the initial members of the Committee have been appointed, develop and publish on the website of the Office of the Assistant Secretary for Preparedness and Response a proposed list of critical need antimicrobial priorities consisting of specific multi-drug resistant bacterial or fungal pathogens, which list shall be developed taking into consideration— (i) specific prevention or treatment of bacterial or fungal infections for which there is an unmet medical need